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Abstract
Background The aim of this study was to evaluate the mid-
term biocompatibility of a new x-shaped implant made of
zirconium in an animal model of glaucoma surgery.
Methods Preoperatively, ultrasound biomicroscopy (UBM),
intraocular pressure (IOP) and outflow facility (OF) data
were acquired. Upon surgery, one eye was chosen randomly
to receive an implant, while the other received none. Ten
rabbits went through a 1-, 2-, 3-, 4- and 6-month follow-up.
IOP was measured regularly, UBM performed at 1, 3 and 6
months after surgery. At the end of the follow-up, OF was
again measured. Histology sections were analyzed.
Results For both groups IOP control was satisfactory, while
OF initially increased at month 1 to resume preoperative
values thereafter. Eyes with implants had larger filtration
blebs which decreased faster than in eyes without the
implant. Drainage vessel density, inflammatory cell number
and fibrosis were higher in tissues near the implant.
Conclusions The zirconium implant initially promoted the
positive effects of the surgery (IOP control, OF increase).
Nevertheless, after several months, foreign body reactions
and fibrosis had occurred on some implants that restrained
the early benefit of such a procedure. Modifications of the
zirconium implant geometry could enhance the overall
success rate.
Keywords Aqueous humour . Drainage device .
Filtering surgery . Glaucoma . Tonometry . Ultrasonography
Introduction
Deep sclerectomy is a non-perforating filtration procedure used
for the surgical treatment of open-angle glaucoma [1–7]. The
key idea was to create an efficient filtration through a natural
membrane without penetrating the anterior chamber. This
would prevent a sudden drop of resistance, thus avoiding
postoperative hypotony and other related complications [5, 6].
The risk of triggering a secondary fibrosis of the filtering
bleb could lead to subsequent failure to efficiently control
IOP. In order to maintain an effective aqueous decompres-
sion space, drainage devices can be implanted in the scleral
space created during surgery [2–7]. These devices differ in
material composition, size, shape, consistency, hydration
ability, and whether or not they can be absorbed [2, 6, 7].
Ceramic biomaterials, like alumina and zirconium, have
been used for decades in orthopaedics [8], dentistry [9, 10]
and otolaryngology [11]. The biocompatibility of these
materials makes them a natural choice for designing a
filtering device which could prevent fibrosis of the filtering
bleb and would not promote scar formation. We were
interested in a neutral material onto which inflammatory
cells would not adhere. The x-shape of the implant was
chosen based on previous clinical results from our group
with devices having the same shape [12]. The aim of this
study was to evaluate the mid-term biocompatibility of a
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new x-shaped implant made of zirconium in an animal
model of glaucoma surgery.
Materials & methods
Study design
Deep sclerectomies were performed on both eyes of ten
New Zealand rabbits. The outflow facility was initially
measured on each eye. One eye was randomly assigned to
the implant group (deep sclerectomy with zirconium
implant, DSZI), the other one to the control group (deep
sclerectomy only, DS). Postoperative follow-up periods
were 1, 2, 3, 4 and 6 months, and included two rabbits per
period. Intraocular pressure was measured three times a
week for the first 2 weeks, then once a week thereafter.
Ultrasound biomicroscopy (UBM) examinations were
performed preoperatively and at 1, 3 and 6 months after
surgery. Rabbits were killed at the end of each follow-up
period. At the end of the inflation test, before the sacrifice,
the outflow facility was measured a second time while
ferritin dye was injected into the anterior chamber. Eyes
were then enucleated and prepared for histology.
Model used
All experiments were performed on pigmented rabbits
weighting 2.5 to 3.5 kg. The animals were kept at 21°C
in a normal 12 hours light/12 hours dark cycle. During all
experiments (UBM, surgery, outflow facility measurement),
general anaesthesia was performed by an intramuscular
injection of a 37.5 mg/kg Ketamin and a 5.0 mg/kg
Xylazine solution. At the end of the follow-up, and while
still under anaesthesia, animals were sacrificed by an
intravascular injection of 3–5 ml of a 65 mg/ml sodium
pentobarbital solution. Experiments have been performed in
compliance with the ARVO statement for the use of
animals in ophthalmic research. (http://www.arvo.org/
AboutArvo/animalst.asp#Recommended)
Implants
The implant was made from medical-grade zirconium
(courtesy Professor Sami Sandhaus, Lausanne, Switzerland)
and was designed in a x-shape measuring 4.0×4.0 mm by
0.8 mm thick (Fig. 1).
Surgical procedure
All deep sclerectomies were performed by the same
experienced surgeon (SR). Details have been published
previously [13]. The implant was secured onto the scleral
bed with a 10/0 nylon suture. After surgery, topical
application of one drop of 5 mg/g tobramycin and 1 mg/g
dexamethasone (Tobradex, Alcon, Fort Worth, TX, USA)
was given twice a day during the first 3 postoperative days,
and once a day for the following 7 days.
Intraocular pressure measurement
Intraocular pressure measurements were performed with a
TONO-Pen-XL tonometer (Mentor, Norwell, MA, USA)
under a drop of local oxybuprocaïn anaesthetic (Novesin,
Novartis Ophtalmics AG, Switzerland) [14]. The mean of
three consecutive readings was recorded preoperatively, and
three times a week postoperatively. To avoid daily and
individual variation, all measurements were performed
between 11 A.M. and 3 P.M. by the same investigator (AB).
Ultrasound biomicroscopy
UBM was performed to follow the evolution of the
operated site [3]. The Humphrey UBM 840 system
(Humphrey Instruments, Inc., San Leandro, CA, USA)
used in B mode provided high-frequency (50 MHz)
Fig. 1 a Macrophotograph of the zirconium implant. Bar: 4 mm. b Scanning electron microscopy of the implant 6 months after surgery. c
Magnification from b
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ultrasonic scan images. The UBM pictures were taken at
the top of the filtration bleb. All examinations were
performed by one single observer (AB) [15].
Outflow facility measurement
To determine the efficacy of deep sclerectomy, outflow
facility was measured just before surgery and at the end of
the follow-up, using an anterior chamber infusion device
under constant pressure. Details have been reported
previously. [13, 16]
The pressure was increased by successive 8-mmHg steps
from baseline IOP up to 32 mmHg. At each pressure level,
a constant pressure was maintained using an appropriate
infusion rate. Four pressure levels were recorded. Infusion
flows were then plotted against pressure and a regression
line was computed, the slope of the curve representing the
outflow facility.
Before killing the animal, a 50 mg/ml cationic ferritin
dye (horse spleen ferritin, MW=800000, Biochemica,
Fluka Chemie, Buchs, Switzerland) was injected through
the catheter into the anterior chamber. While maintaining
the IOP slightly over 25 mmHg, the ferritin dye was
allowed to diffuse into the trabecular meshwork and the
new drainage vessels for about 15 minutes.
Histology
The implants were explanted after enucleation, and classi-
cally prepared for scanning electronic microscopy. The eyes
were prepared for optical microscopy, and sections were
stained with haematoxylin-eosin (HE) to identify inflam-
matory cells. Haematoxylin-eosin plus Prussian blue
revealed the ferritin in the drainage vessels, while the
Goldner trichrome allowed visualization of fibrosis. [16]
Under a 10× magnification, the number of inflammatory
cells and drainage vessels were counted for each eye in five
consecutive sections at the surgical site and on native sclera.
Results were expressed as the difference, and the ratio of
vessels counted in the operated and native region. The
scarring response was assessed based on the inflammatory
cell density and fibrosis thickness in relation to the implant.
Statistics
The results were expressed as the mean and standard
deviation (mean±SD). Parametric comparison between
means was performed using the unpaired two-tailed
Student’s t-test, and non-parametric comparison was com-
puted with the Mann-Whitney U test. Results were
considered significant when p<0.05.
Results
Intraocular pressure
The initial post-operative pressure drop was followed by a
new steady state in both groups (Fig. 2). In the zirconium
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Fig. 2 Intraocular pressure profile (IOP) before and after deep
sclerectomy with (DSZI) and without (DS) zirconium implant during
the 6-month follow-up. The initial postoperative drop was followed by
a new steady state
Fig. 3 Ultrasonic biomicro-
scopy preoperatively (a), and at
1 month post deep sclerectomy
with (b) a zirconium implant.
ac: anterior chamber, c: cornea,
cb: ciliary body, i: iris, ib: intra-
scleral filtration bleb, s: sclera,
tdm: trabeculo-Descemet’s
membrane, zi: zirconium
implant
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implant group, IOP dropped by 25% at 6 months from a
mean preoperative value of 13.4 mmHg (±2.46). In the
control group, IOP dropped by 32% from a mean
preoperative value of 13.9 mmHg (±3.35). The IOP drop
after surgery was statistically significant in comparison with
the preoperative values, (p<0.002), but the difference in
IOP at the end of each follow-up period between both
groups was not statistically significant (p=0.3).
Ultrasound biomicroscopy
The intrascleral and subconjonctival filtration blebs were
visible on each surgical site for each eye of both groups at
1, 3 and 6 months postoperatively (Fig. 3). Both intrascleral
and subconjonctival filtration blebs were thicker in the
zirconium implant group than in the group without implant
on every observation, but these differences didn’t reach a
significant level except for the first and third months (Table 1).
Outflow facility
A slight difference in the mean preoperative outflow
facility between right 0.34 μl /mmHg min (±0.11) and
left 0.43 μl /mmHg min (±0.13) eyes was noted, but was
not considered statistically significant (p=NS). Mean
outflow facility in the control group reached maximal values
during the first (0.6 μl/mmHgmin) and second postoperative
month (0.5 μl/mmHgmin), and gradually decayed to reach a
plateau similar to the preoperative value. On the other hand,
mean outflow facility for the implant group slightly increased
1 month after surgery, and dropped to lower values than
preoperative control for the rest of the study (p=0.15) (Fig. 4).
Histology
In both groups, light microscopy analysis performed 1, 2, 3
and 4 months after surgery revealed the presence of a
slightly higher mean number of outflow vessels in the
sclera at the surgical site (10.6 for the DS group and 15.4
for the DSZI group respectively) compared to the native
sclera (2.6). The difference between the surgical and native
sclera was clearly significant (p<0.001). After 6 months
there were no longer drainage vessels visible (Table 2).
Throughout the entire follow-up, the number of drainage
channels in the surgical site was higher in the DSZI group
compared to the DS group, the difference being also
statistically significant (p<0.001). During the entire follow
up, a higher number of inflammatory vessels in the surgical
site compared to the native sclera were visible in both
groups (Table 3) (p<0.001), and this number was more
important in the DSZI group than in the DS group.
The empty space of the extracted implant was lined with
fibroblasts. The fibroblast reaction was already present 1
month after surgery, and increased throughout the 6-month
study (Fig. 5 and Table 3). We have also noticed the
presence of an inflammatory reaction, essentially composed
of giant cells around the suture material, that were barely
visible at 1 month, but which were more pronounced at 6
months (Fig. 5).
Discussion
Our study aims to assess the biocompatibility and efficiency
of a zirconium implant in deep sclerectomy using an animal
model. This implant being non-resorbable, it should be
adequate to preserve an intrascleral space and to maintain
good filtration, and the x-shape should increase the volume
of the filtration bleb.
Table 1 Comparison between the mean intrascleral and subconjonctival bleb thickness (mm) measured on UBM
Intrascleral bleb Subconjunctival bleb P
DS DSZI DS DSZI Intrascleral Subconjunctival
One month 0.36 (±0.10) 0.77 (±0.16) 0.26 (±0.03) 0.51 (±0.14) <0.001 0.45
Three months 0.26 (±0.09) 0.65 (±0.09) 0.20 (±0.01) 0.39 (±0.05) <0.001 0.42
Six months 0.27 (±0.18) 0.55 (±0.21) 0.17 (±0.02) 0.38 (±0.18) 0.3 0.28
Legend: deep sclerectomy with (DSZI) and without (DS) zirconium implant
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0 1 2 3 4 6
Months
O
ut
flo
w
 fa
ci
lit
y(u
l/m
in/
mm
Hg
)
Preoperative DS DSZI
Fig. 4 Comparison of preoperative and postoperative mean outflow
facility (OF) in DSZI and DS during the 6-month follow-up
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Our study showed a postoperative IOP-lowering effect in
both DS and DSZI groups achieved soon after surgery,
followed by a slight increase 3 months after surgery. This
tendency was not incredibly surprising because, firstly, the
animals used were non-glaucomatous, and secondly, an
adaptation to the surgically modified outflow facility was
conceivable. Similarly, an increased aqueous production
would counter the increased outflow facility.
While the thickness of both subconjonctival and intra-
scleral filtration blebs was larger in the DSZI group than the
DS-only group, we still observed a faster subconjonctival
and intrascleral bleb thickness reduction in the DSZI group
than in the DS group, which could be explained by a
inflammatory reaction that induced fibrosis.
After performing a deep sclerectomy, removing the main
obstacle to aqueous humour outflow, we would have
anticipated a marked and sustained increase in the outflow
facility over time. This increase was noticed for both
groups during the first month only. For the following 5
months, the outflow facility progressively decreased to
reach preoperative values. This reduction in outflow facility
could be explained by the occurrence of tissue remodelling
at the surgical site or around the filtering bleb, induced or
promoted by the surgery and or the implant. This reaction
was apparently more important in the DSZI group.
Light microscopy showed the development of new
intrascleral drainage ducts around the surgical site, which
were slightly more important in the zirconium implant
group, thus supporting the hypothesis that the implant was
enhancing development and growth of new vessels in the
surgical bed. Histological detection of drainage vessels was
limited to the ferritin measurement. Ethier and Chan
demonstrated in a study on human eyes that cationic
ferritin reduces the outflow facility, presumably by binding
to negatively charged sites in the outflow pathway, at the
inner wall of Schlemm’s canal [17]. To avoid methodolog-
ical bias in measuring outflow facility affected by such a
drawback, we have infused only for a brief period (15
minutes) in the anterior chamber, which should explain low
ferritin coloration on the sections.
The drainage space was lined with spindle cells at the
implant location and surrounded by fibrosis. In the deep
sclerectomy-only sections, an irregular canal without spindle
cells was observed. Contrary to the other non-absorbable
implants (HEMA, PMMA) which are soft, the zirconium
implant is very hard. This results in a huge difference in
compliance when compared to the more flexible eye tissues.
This strong difference between the implant and the sclera
could be responsible for micro movements of the implant
during the microscopic sclera expansion, and contraction
during the circadian IOP changes. These movements were
sufficient to induce a significant shear at the interface,
resulting in a chronic inflammatory response and leading to
important scarring around the zirconium implant in the later
phases. The quality of the implant surface could also have
played a particular role in this complication. Imperfectly
Table 3 Comparison between the mean numbers of inflammatory channels observed with light microscopy. Deep sclerectomy with (DSZI) and
without (DS) zirconium implant
Surgical site Non surgical site New channels
DS DSZI DS DSZI DS DSZI
1 month 6.05 (±1.48) 12.90 (±2.69) p<0.001 1.55 (±0.49) 2.35 (±0.21) p<0.05 4.50 10.55
2 months 7.15 (±0.49) 15.10 (±2.12) p<0.001 3.25 (±1.06) 2.30 (±0.14) p<0.05 3.95 12.80
3 months 5.77 (±0.80) 13.70 (±0.71) p<0.001 2.60 (±0.85) 2.85 (±0.21) † 3.17 10.85
4 months 7.20 (±2.63) 10.40 (±3.68) p<0.01 1.95 (±0.78) 1.00 (±0.28) † 5.25 9.40
6 months 10.60 (±2.26) 15.37 (±2.30)p<0.001 2.70 (±0.42) 2.35 (±1.20) † 7.9 13
†=NS
Table 2 Comparison between the mean numbers of drainage vessels observed with light microscopy. Thickness of the fibrosis around the
implant. Deep sclerectomy with (DSZI) and without (DS) zirconium implant
Surgical site Non surgical site New channels Fibrosis (μm)
DS DSZI DS DSZI DS DSZI DSZI
1 month 0.30 (±0.42) 2.70 (±3.81) p<0.001 0.25 (±0.07) 0.30 (±0.42) † 0.05 2.4 131.25 (±8.8)
2 months 0.25 (±0.35) 0.80 (±0.28) p<0.001 0.10 (±0.14) 0.00 (±0.00) † 0.15 0.80 118.75 (±8.8)
3 months 0.00 (±0.00) 0.30 (±0.42) † 0.00 (±0.00) 0.25 (±0.35) † 0.05 0.15 75 (±0.00)
4 months 1.25 (±0.35) 1.80 (±1.69) p<0.01 0.50 (±0.48) 0.00 (±0.00) † 0.75 1.80 137.5 (±17.68)
6 months 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 0.00 (±0.00) 0.00 0.00 162.5 (±53.03)
†=NS
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polished surfaces, sharp edges or too thick an implant could
have worsened the inflammatory response (Fig. 1b). The
effect of the implant on the surgical site seemed to be
influenced not only by the material used, which is known to
have a good intrinsic biocompatibility, but also by other
geometrical features causing interferences in this study. The
data based on histology supports the hypothesis that the
zirconium implant in our model promotes scar formation
rather than preventing such reaction. In the context of the
filtering surgery, such implant failed to prevent formation of
fibrosis, a reported complication of the glaucoma surgery.
The surface of the implant was not massively invaded by
inflammatory cells (Fig. 1b), which validated the initial
hypothesis that the material would not be prone to cell
adhesion. Adverse events affecting the surrounding tissues
could have triggered a foreign-body reaction in the presence
of the implant, thus promoting the fibrosis around the device
instead of limiting the extent of the scarring response.
The general conclusions of this study were limited by a
few factors. These rabbits were not suffering from
glaucoma, and the anatomy of their eyes was normal in
all respects. The number of experiments conducted was
somewhat too small to draw a definitive conclusion on
glaucoma surgery with ceramic implants. Further studies
should be performed to determine the real biocompatibility
of this implant in glaucoma surgery.
In conclusion, this study reported results of experimental
non-penetrating glaucoma surgery with zirconium implants
on rabbit eyes. Initial IOP drop after surgery was followed
by a slow return to preoperative values. UBM images show
intrascleral and subconjunctival filtering blebs to be larger
in the zirconium group. Bleb height was progressively
reduced until the 6th month. Outflow facility was signifi-
cantly increased in eyes having only non-penetrating
surgery without implant for the first 2 months, and returned
to normal thereafter. Zirconium-implanted eyes have not
shown any significant increase in outflow facility after
surgery. From histology, we observed that the number of
drainage vessels were slightly higher for the zirconium
group compared to the group without the implant. Fibrosis,
scar formation and inflammatory response were significant-
ly more pronounced in the zirconium group. These
reactions were probably the main reason for the relative
failure in this implant surgery despite well-known biocom-
patibility of this material in bioprosthesis. As it stands, this
implant failed to prevent the scarring response of the
filtering bleb in an experimental model of glaucoma
surgery. Modifications of the zirconium implant geometry
could enhance the overall success rate.
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